Manufacturer: Dragon Pharma
Category: Injectable Steroids
Substance: Trenbolone acetate
Package: 10 ml vial (50 mg/ml)
Trenbolone 50 Dragon Pharma – one of the most powerful anabolic steroids, promotes the active growth of muscle mass and strength.
With proper preparation of the course, the reception guarantees a set of up to 10 kg of weight for 8 weeks. The growth of strength and muscle mass is largely due to an increase of 200% insulin-like factor, and the stimulation of growth hormone contributes to fat burning.
When you receive trenbolone, there is a significant increase in libido and a decrease in the level of cortisol in the blood.
The detection period in the blood – up to 5 months.
Instructions for use
Since trenbolone is a very strong anabolic, it should be taken very carefully in order to avoid the occurrence of side effects.
The following dosage is considered optimal:
Trenbolone acetate – no more than 50 mg per day or 100 mg every other day by injection
Trenbolone enanthate and other forms – no more than 300 mg per week, injections are made 1 time per week
Since the production of own testosterone decreases, from the second week of taking the drug it is recommended to include gonadotropin in the course. Without gonadotropin, taking trenbolone for more than 5-6 weeks is not recommended.
2 weeks after the last injection, post-course therapy (Clomid or toremifene) should be started.
The best effect of taking trenbolone is achieved while maintaining a diet for gaining muscle mass and taking sports nutrition.
There is no need to combine trenbolone with other steroids during the period of gaining muscle mass. During the drying period, you can enter into the course anavar or winstrol at a dosage of 50% of the usual. In this case, the intake of anti-estrogens is not required.
Strong anabolic effect of trenbolone causes the incidence of side effects.
The most common side effects of taking trenbolone are:
- blood pressure rise
- baldness, acne
- decrease in libido, deterioration of erection, atrophy
There are no reviews yet.